Immunohistochemical demonstration of Epstein-Barr virus nuclear antigens 1 and 2 in post-transplant lymphoproliferative disorders

Applied Immunohistochemistry and Molecular Morphology

Volumn 4, Issue 2, 1996, Pages 102-105

  Chetty, R ^a,e   Biddolph, S ^b   Kaklamanis, L ^a   Kremmer, E ^d   Cary, N ^c   Stewart, S ^c   Parameshuar, J ^c   Giatromanolaki, A ^a   Gatter, K ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^c PAPWORTH HOSPITAL   (United Kingdom)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY OF NATAL   (South Africa)

Author keywords

EBNA 1; EBNA 2; Epstein Barr virus; Lymphoproliferative disorders; Transplants

Indexed keywords

MONOCLONAL ANTIBODY; VIRUS ANTIGEN;

ARTICLE; CLINICAL ARTICLE; EPSTEIN BARR VIRUS; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; TRANSPLANTATION;

EID: 0029938163     PISSN: 10623345     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Ho M, Muller G, Atchison RW, et al. Epstein-Barr virus infections and DNA hybridsation studies in posttransplantation lymphoma and lymphoproliferative lesions. The role of the primary infection. J Infect Dis 1985;152:876-86.
2. Wilkinson AH, Smith JL, Hanicker LG, et al. Increased frequency of post-transplant lymphomas in patients treated with cyclosporine, azothioprine, and prednisone. Transplantation 1989;47:293-6.
3. Thiru S, Calne RY, Nagington J. Lymphoma in renal allograft patients treated with cyclosporin-A as one of the immunosuppressive agents. Transplant Proc 1981;13:359-64.
4. Crawford DH, Thomas JA, Janossy G, et al. Epstein-Barr nuclear antigen positive lymphoma after cyclosporin A treatment in patients with renal allograft. Lancet 1980;1:1355-6.
5. Hanto DW, Frizzera G, Purtilo DT, et al. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus. Cancer Res 1981;41:4253-61.
6. Starzl TE, Nalesnik MA, Porter KA, et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 1984;1:583-7.
7. Oudejans JJ, Jiwa M, van den Brule AJC, et al. Detection of heterogenous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 1995;147:923-33.
8. McKnight JLC, Cen H, Riddler SA, et al. EBV gene expression, EBNA antibody responses and EBV+ peripheral blood lymphocytes in post-transplant lymphoproliferative disease. Leuk Lymphoma 1994;15:9-16.
9. Sample C, Kieff E. Molecular basis for Epstein-Barr virus induced pathogenesis and disease. Semin Immunopathol 1991;13:133-46.
10. Kieff E, Liebowitz D. Epstein-Barr virus and its replication. In: Fields BN, Knipe DM, eds. Virology. New York: Raven Press, 1990:1889.
11. Ring CJA. The B-cell immortalizing functions of Epstein-Barr virus. J Gen Virol 1994;75:1-13.
12. Nalesnik M, Jaffe R, Starzl TE, et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988;133:173-92.
13. Grasser FA, Murray PG, Kremmer E, et al. Monoclonal antibodies directed against the Epstein-Barr virus-encoded nuclear antigen 1 (EBNA I): immunohistologic detection of EBNA 1 in the malignant cells of Hodgkin's disease. Blood 1994;84:3792-8.
14. Chan JKC, Yip TTC, Tsang WYW, et al. Detection of Epstein-Barr viral RNA in malignant lymphomas of the upper aerodigestive tract. Am J Surg Pathol 1994;18:938-46.
15. Klein G. Viral latency and transformation: the strategy of Epstein-Barr virus. Cell 1989;58:5-8.
16. Gratama JW, Zutter MM, Minarovits J, et al. Expression of Epstein-Barr virus-encoded growth transformation-associated proteins in lymphoproliferations of bone marrow transplant recipients. Int J Cancer 1991;47:188-92.
17. Young LS, Alfieri C, Hennessy K, et al. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease. N Engl J Med 1989;321:1080-5.
18. Cen H, Williams PA, McWilliams HP, et al. Evidence for restricted Epstein-Barr virus latent gene expression and anti-EBNA antibody response in solid organ transplant recipients with posttransplant lymphoproliferative disorders. Blood 1993;81:1393-403.
19. Khan G, Naase MA. Down-regulation of Epstein-Barr virus nuclear antigen 1 in Reed-Sternberg cells of Hodgkin's disease. J Clin Pathol 1995;48:845-8.